Phio Pharmaceuticals Corp. is a U.S.-based company dedicated to creating immune-system-focused cancer treatments. Their proprietary INTASYL therapeutic platform aims to influence both tumor and immune cells through the precise regulation of immune system genes. The company's pipeline includes several key candidates for adoptive cell transfer (ACT): PH-762 works by diminishing the expression of the PD-1 checkpoint protein, thereby empowering immune cells to identify and eliminate cancerous cells; PH-894, another candidate, silences BRD4, an epigenetic protein crucial for intracellular gene expression regulation; and PH-804 is designed to target TIGIT, a suppressive immune receptor and checkpoint protein found on T cells and natural killer cells. Furthermore, the company maintains a partnership with AgonOx Inc. to advance the clinical development of innovative T cell-based immunotherapies for cancer. Incorporated in 2011, Phio Pharmaceuticals Corp., headquartered in Marlborough, Massachusetts, adopted its current name in November 2018, having previously operated as RXi Pharmaceuticals Corporation.
